{"title":"Investigation of Left Atrial Spontaneous Echo Contrast as a Marker Indicating Ineffective Anticoagulation in Patients with Mitral Valve Replacement Receiving Warfarin Spontaneous Echo Contrast Indicates Stroke","authors":"E. E. Güntürk, M. Demirbaş, Y. Doğan, S. Doğan, I. Gunturk","doi":"10.14744/EJMI.2019.29093","DOIUrl":"https://doi.org/10.14744/EJMI.2019.29093","url":null,"abstract":"DOI: 10.14744/ejmi.2019.29093 EJMI 2019;3(2):163–168","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132583426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.30689
E. Atağ
Objectives: Bladder cancer predominantly affects the elderly and exhibits poor survival in the metastatic stage, where the five-year survival rate is approximately 15% with contemporary regimens. Geriatric patients with metastatic bladder cancer generally have low-performance status and multiple comorbid diseases, therefore they often are unable to receive optimal therapy. We aimed to evaluate the rate of metastatic bladder cancer patients receiving systemic treatment, chemotherapy regimens, response to treatments, survival data, and factors influencing mortality. Methods: Patients with metastatic bladder cancer who were treated at our clinic between January 2011 and October 2021 were retrospectively reviewed. Factors affecting survival were evaluated using the long-rank test. Multivariate analysis was performed using cox regression. Results: A total of 121 patients with metastatic disease were included in the study. The median age of the patients was 68 (41-86) years. The median overall survival was 9 months. Overall one-, two- and five-year survival rates were 31%, 17%, and 0.5%, respectively. 52 (43%) of the patients died without receiving any systemic treatment at the metastatic stage. The median overall survival was 3.3 months in patients who received no systemic therapy at the metastatic stage, while it was 11.6 months in patients who received at least one line of therapy (p<0.01). The presence of liver metastasis (HR 1.9; %95 CI 1.17 to 3.09; p<0.01) and the absence of systemic treatment in the metastatic stage (HR 4.26; %95 CI 2.81 to 6.46; p<0.01) were among the independent risk factors for mortality. The rate of patients aged 65 and over was higher in the group not receiving chemotherapy (71.2% vs 47.8%, p=0.01). While 76.9% of the patients who did not receive chemotherapy had recurrent disease, this rate was 49.3% in the group receiving chemotherapy (p<0.01). Conclusion: Nearly half of the patients with metastatic bladder cancer died without any systemic treatment. Independent risk factors associated with mortality included absent treatment and the presence of liver metastasis. Patients who did not receive treatment were older and had higher rates of recurrent metastatic disease. Abstract Article: Factors Influencing Mortality of Metastatic Single-Center
目的:膀胱癌主要影响老年人，在转移期表现出较差的生存率，在现代治疗方案下，5年生存率约为15%。老年转移性膀胱癌患者通常表现不佳，并伴有多种合并症，因此往往无法获得最佳治疗。我们的目的是评估转移性膀胱癌患者接受全身治疗的比率、化疗方案、对治疗的反应、生存数据和影响死亡率的因素。方法:回顾性分析2011年1月至2021年10月在我院治疗的转移性膀胱癌患者。使用长秩检验评估影响生存的因素。采用cox回归进行多因素分析。结果:共有121例转移性疾病患者被纳入研究。患者的中位年龄为68(41-86)岁。中位总生存期为9个月。总的1年、2年和5年生存率分别为31%、17%和0.5%。52例(43%)患者在转移期未接受任何全身治疗而死亡。在转移期未接受全身治疗的患者中位总生存期为3.3个月，而接受至少一种治疗的患者中位总生存期为11.6个月(p<0.01)。存在肝转移(HR 1.9;%95 CI 1.17 - 3.09;p<0.01)和转移期未进行全身治疗(HR 4.26;%95 CI 2.81 - 6.46;P <0.01)是死亡率的独立危险因素。65岁及以上患者未接受化疗组发生率较高(71.2% vs 47.8%， p=0.01)。未接受化疗的患者有76.9%复发，而接受化疗的患者有49.3%复发(p<0.01)。结论:近一半的转移性膀胱癌患者未经任何系统治疗而死亡。与死亡率相关的独立危险因素包括缺乏治疗和存在肝转移。未接受治疗的患者年龄较大，并且有较高的复发转移性疾病发生率。文章:影响转移性单中心肿瘤死亡率的因素
{"title":"Factors Influencing Mortality of Metastatic Bladder Cancer: A Single-Center Experience","authors":"E. Atağ","doi":"10.14744/ejmi.2022.30689","DOIUrl":"https://doi.org/10.14744/ejmi.2022.30689","url":null,"abstract":"Objectives: Bladder cancer predominantly affects the elderly and exhibits poor survival in the metastatic stage, where the five-year survival rate is approximately 15% with contemporary regimens. Geriatric patients with metastatic bladder cancer generally have low-performance status and multiple comorbid diseases, therefore they often are unable to receive optimal therapy. We aimed to evaluate the rate of metastatic bladder cancer patients receiving systemic treatment, chemotherapy regimens, response to treatments, survival data, and factors influencing mortality. Methods: Patients with metastatic bladder cancer who were treated at our clinic between January 2011 and October 2021 were retrospectively reviewed. Factors affecting survival were evaluated using the long-rank test. Multivariate analysis was performed using cox regression. Results: A total of 121 patients with metastatic disease were included in the study. The median age of the patients was 68 (41-86) years. The median overall survival was 9 months. Overall one-, two- and five-year survival rates were 31%, 17%, and 0.5%, respectively. 52 (43%) of the patients died without receiving any systemic treatment at the metastatic stage. The median overall survival was 3.3 months in patients who received no systemic therapy at the metastatic stage, while it was 11.6 months in patients who received at least one line of therapy (p<0.01). The presence of liver metastasis (HR 1.9; %95 CI 1.17 to 3.09; p<0.01) and the absence of systemic treatment in the metastatic stage (HR 4.26; %95 CI 2.81 to 6.46; p<0.01) were among the independent risk factors for mortality. The rate of patients aged 65 and over was higher in the group not receiving chemotherapy (71.2% vs 47.8%, p=0.01). While 76.9% of the patients who did not receive chemotherapy had recurrent disease, this rate was 49.3% in the group receiving chemotherapy (p<0.01). Conclusion: Nearly half of the patients with metastatic bladder cancer died without any systemic treatment. Independent risk factors associated with mortality included absent treatment and the presence of liver metastasis. Patients who did not receive treatment were older and had higher rates of recurrent metastatic disease. Abstract Article: Factors Influencing Mortality of Metastatic Single-Center","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130100039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An Effective Method for Intramedullary Fixation of Long Bone Fractures Reducing the Operative Duration and Flouroscopy Time: Guide Wire Assisted Nail Locking","authors":"A. Barış","doi":"10.14744/ejmi.2022.44901","DOIUrl":"https://doi.org/10.14744/ejmi.2022.44901","url":null,"abstract":"DOI: 10.14744/ejmi.2022.44901 EJMI 2022;6(1):38–44","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130280258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Computed tomography findings of peritoneal dialysis related complications","authors":"E. Yılmaz, İ. Kurultak, S. Ustundag, N. Tunçbilek","doi":"10.14744/EJMI.2019.12015","DOIUrl":"https://doi.org/10.14744/EJMI.2019.12015","url":null,"abstract":"DOI: 10.14744/ejmi.2019.12015 EJMI 2019;3(1):19–22","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"49 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114023636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Relationship between Rheumatoid Arthritis Activation Criteria and Serum Hepcidin Levels","authors":"E. T. Bekmez, O. Volkan, N. Demi̇r, E. Erkek, D. Taşan, M. Aliustaoğlu","doi":"10.14744/ejmi.2019.74073","DOIUrl":"https://doi.org/10.14744/ejmi.2019.74073","url":null,"abstract":"DOI: 10.14744/ejmi.2019.74073 EJMI 2019;3(4):275–279","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114459216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2023.79007
A. Ozveren
: To demonstrate that the neutrophil/lymphocyte ratio (NLR) and modified Glasgow Prognostic Score (mGPS) are negative prognostic factors for overall survival and mGPS is a more sensitive marker in patients diagnosed with stage 4 pancreatic cancer (PC). Methods: A total of 68 patients with stage 4 PC were included in the study. Clinical and laboratory data were collected and evaluated in the form of retrospective file scanning. Analysis was performed using the SPSS database. Results: The median age at diagnosis was 67 years, the median progression-free survival (PFS) was 5.2 months, and the median overall survival (OS) was 11.1 months. OS was 18.1 months in patients with low NLR and 10.4 months in patients with high NLR (*p=0.013). OS was 21.3 months in patients with an mGPS of 0, 10.3 months in patients with an mGPS of 1, and 5.5 months in patients with an mGPS of 2 (*p=0.001). Conclusion: Eastern Cooperative Oncology Group (ECOG) performance status score, NLR, and mGPS are unfavorable prognostic factors for OS in stage 4 PC. mGPS is a more sensitive prognostic factor than both ECOG performance status score and NLR.
{"title":"The Effect of the Modified Glasgow Prognostic Score and Neutrophil/Lymphocyte Ratio on Prognosis in Stage 4 Pancreatic Cancer","authors":"A. Ozveren","doi":"10.14744/ejmi.2023.79007","DOIUrl":"https://doi.org/10.14744/ejmi.2023.79007","url":null,"abstract":": To demonstrate that the neutrophil/lymphocyte ratio (NLR) and modified Glasgow Prognostic Score (mGPS) are negative prognostic factors for overall survival and mGPS is a more sensitive marker in patients diagnosed with stage 4 pancreatic cancer (PC). Methods: A total of 68 patients with stage 4 PC were included in the study. Clinical and laboratory data were collected and evaluated in the form of retrospective file scanning. Analysis was performed using the SPSS database. Results: The median age at diagnosis was 67 years, the median progression-free survival (PFS) was 5.2 months, and the median overall survival (OS) was 11.1 months. OS was 18.1 months in patients with low NLR and 10.4 months in patients with high NLR (*p=0.013). OS was 21.3 months in patients with an mGPS of 0, 10.3 months in patients with an mGPS of 1, and 5.5 months in patients with an mGPS of 2 (*p=0.001). Conclusion: Eastern Cooperative Oncology Group (ECOG) performance status score, NLR, and mGPS are unfavorable prognostic factors for OS in stage 4 PC. mGPS is a more sensitive prognostic factor than both ECOG performance status score and NLR.","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"73 5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131818587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Burnout Among Medical Oncology Physicians and Related Factors: A Nationwide Survey","authors":"O. Avcı","doi":"10.14744/ejmi.2021.93667","DOIUrl":"https://doi.org/10.14744/ejmi.2021.93667","url":null,"abstract":"DOI: 10.14744/ejmi.2021.93667 EJMI 2021;5(3):301–308","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"225 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131972386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.15567
H. Semiz
Objectives: Due to limited data in the literature on the prognostic value of inflammatory markers neutrophil/lympho-cyte ratio (NLR), platelet/lymphocyte ratio (PLR), and derived NLR (dNLR) in metastatic castration-sensitive prostate cancer (mCSPC), we aimed to determine the role of this markers in the prognosis of mCSPC. Methods: In this study, inflammatory marker values in mCSPC (NLR0, PLR0, dNLR0) and mCRPC (NLR1, PLR1, dNLR1) were calculated. Characteristics of the patients and the effects of inflammatory markers on overall survival (OS) and cancer-specific survival (CSS) were evaluated using appropriate statistical methods. Results: The median age of 124 patients was 68.71 years. No significant difference was found OS in mCSPC NLR0, dNLR0 and PLR0 groups (p>0,05). While the median CSS was statistically longer in the NLR0, dNLR0 and PLR0 low groups (Median:45.9 vs 35.7 months for NLR0, 47.0 vs 34.6 months for dNLR and 46.2 vs 33.9 months, p=0.037, p=0.036, p=0.041 respectively). There was no significant difference in terms of OS and CSS in NLR1 and dNLR1 groups (p>0.05). The patients with low PLR1 showed statistical significantly better OS and CSS (p=0.027 for OS and p=0.006 for CSS). Conclusion: Although inflammatory markers have prognostic value in many cancers, mCSPC which have heteroge-neous and complex structures, are still controversial, and more studies are needed for their routine use. Abstract
{"title":"The Prognostic Role of Inflammatory Biomarkers in Metastatic Castration Sensitive Prostate Carcinoma","authors":"H. Semiz","doi":"10.14744/ejmi.2022.15567","DOIUrl":"https://doi.org/10.14744/ejmi.2022.15567","url":null,"abstract":"Objectives: Due to limited data in the literature on the prognostic value of inflammatory markers neutrophil/lympho-cyte ratio (NLR), platelet/lymphocyte ratio (PLR), and derived NLR (dNLR) in metastatic castration-sensitive prostate cancer (mCSPC), we aimed to determine the role of this markers in the prognosis of mCSPC. Methods: In this study, inflammatory marker values in mCSPC (NLR0, PLR0, dNLR0) and mCRPC (NLR1, PLR1, dNLR1) were calculated. Characteristics of the patients and the effects of inflammatory markers on overall survival (OS) and cancer-specific survival (CSS) were evaluated using appropriate statistical methods. Results: The median age of 124 patients was 68.71 years. No significant difference was found OS in mCSPC NLR0, dNLR0 and PLR0 groups (p>0,05). While the median CSS was statistically longer in the NLR0, dNLR0 and PLR0 low groups (Median:45.9 vs 35.7 months for NLR0, 47.0 vs 34.6 months for dNLR and 46.2 vs 33.9 months, p=0.037, p=0.036, p=0.041 respectively). There was no significant difference in terms of OS and CSS in NLR1 and dNLR1 groups (p>0.05). The patients with low PLR1 showed statistical significantly better OS and CSS (p=0.027 for OS and p=0.006 for CSS). Conclusion: Although inflammatory markers have prognostic value in many cancers, mCSPC which have heteroge-neous and complex structures, are still controversial, and more studies are needed for their routine use. Abstract","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132289989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.90199
Ashley Rebecca Guishard
Lung cancer is the leading cause of cancer-related deaths in Western countries.[1] Even though vast amounts of resources have been allocated for both basic and clinical research to find a cure for this disease, the prognosis for lung cancer is still poor.[1] For instance, the 5-year relative survival rate for patients diagnosed the 1970s was about 12% and increased only to 18% for those diagnosed between 2003 and 2009.[2] During those decades, important advances in the understanding of lung cancer biology have been accomplished. One of the breakthrough discovery in cancer research has been the isolation in 2005 of putative lung cancer stem-like cells (CS-LCs)[3] and their association with chemoresistance.[4] Lung CSCs (LCSCs) constitute a subpopulation of cancer cells (accounting for 0.03-6.1% of the cell population) that can regenerate a heterogeneous tumor. This discovery has led to the assumption that if CSCs were eliminated, the cancer would be cured. It is then expected that clinical trials performed after 2005 will focus in eliminating LCSCs. The poor advance in the treatment of lung cancer is somehow similar to what have been described for other tumors. For instance, glioma patients’ prognosis has remained the same during the last four decades. In this type of tumor, we have previously described a translational gap, defined as a delay in the application of rudimentary cancer cell biological concepts in the design of clinical trials.[6] In particular, we found that key concepts, such as the importance of the blood brain barrier and the existence of glioma stem cells, are seldom incorporated in Phase I/II clinical trials. These explain, at least in part, the failure of most clinical trials and why the prognosis of glioma patients remains similar to decades ago. Ashley Rebecca Guishard,1,2 Juan Sebastian Yakisich,3 Neelam Azad,3 Anand Krishnan V. Iyer3
肺癌是西方国家癌症相关死亡的主要原因。[1]尽管已经投入了大量的资源用于基础研究和临床研究，以找到治疗这种疾病的方法，但肺癌的预后仍然很差。[1]例如，20世纪70年代确诊的患者的5年相对存活率约为12%，而2003年至2009年间确诊的患者的5年相对存活率仅上升至18%。[2]在那几十年里，对肺癌生物学的理解取得了重要进展。癌症研究的一个突破性发现是在2005年分离出假定的肺癌干细胞(cs - lc)[3]及其与化疗耐药的关系[4]。肺间充质干细胞(LCSCs)是一种能够再生异质肿瘤的癌细胞亚群(占细胞群的0.03-6.1%)。这一发现导致了一种假设，即如果消除csc，癌症就会被治愈。预计2005年以后进行的临床试验将集中于消除LCSCs。肺癌治疗进展缓慢，与其他肿瘤的治疗进展类似。例如，神经胶质瘤患者的预后在过去四十年中一直保持不变。在这种类型的肿瘤中，我们之前描述过一个翻译缺口，定义为在临床试验设计中应用基本癌细胞生物学概念的延迟。[6]特别是，我们发现关键概念，如血脑屏障的重要性和胶质瘤干细胞的存在，很少被纳入I/II期临床试验。这些至少部分解释了大多数临床试验的失败，以及为什么神经胶质瘤患者的预后与几十年前相似。Ashley Rebecca Guishard,1,2 Juan Sebastian Yakisich,3 Neelam Azad,3 Anand Krishnan V. Iyer3
{"title":"Translational Gap in Lung Cancer Research","authors":"Ashley Rebecca Guishard","doi":"10.14744/ejmi.2022.90199","DOIUrl":"https://doi.org/10.14744/ejmi.2022.90199","url":null,"abstract":"Lung cancer is the leading cause of cancer-related deaths in Western countries.[1] Even though vast amounts of resources have been allocated for both basic and clinical research to find a cure for this disease, the prognosis for lung cancer is still poor.[1] For instance, the 5-year relative survival rate for patients diagnosed the 1970s was about 12% and increased only to 18% for those diagnosed between 2003 and 2009.[2] During those decades, important advances in the understanding of lung cancer biology have been accomplished. One of the breakthrough discovery in cancer research has been the isolation in 2005 of putative lung cancer stem-like cells (CS-LCs)[3] and their association with chemoresistance.[4] Lung CSCs (LCSCs) constitute a subpopulation of cancer cells (accounting for 0.03-6.1% of the cell population) that can regenerate a heterogeneous tumor. This discovery has led to the assumption that if CSCs were eliminated, the cancer would be cured. It is then expected that clinical trials performed after 2005 will focus in eliminating LCSCs. The poor advance in the treatment of lung cancer is somehow similar to what have been described for other tumors. For instance, glioma patients’ prognosis has remained the same during the last four decades. In this type of tumor, we have previously described a translational gap, defined as a delay in the application of rudimentary cancer cell biological concepts in the design of clinical trials.[6] In particular, we found that key concepts, such as the importance of the blood brain barrier and the existence of glioma stem cells, are seldom incorporated in Phase I/II clinical trials. These explain, at least in part, the failure of most clinical trials and why the prognosis of glioma patients remains similar to decades ago. Ashley Rebecca Guishard,1,2 Juan Sebastian Yakisich,3 Neelam Azad,3 Anand Krishnan V. Iyer3","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133824596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：